🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

22 results for “Xenon Pharmaceuticals” Clear

  1. Azetukalner

    Xenon Pharmaceuticals

    Bipolar Depression

    phase 3 small molecule active

    1 trial

  2. Azetukalner

    Xenon Pharmaceuticals

    Major Depressive Disorder

    phase 3 small molecule active

    3 trials

  3. Azetukalner

    Xenon Pharmaceuticals

    Bipolar Disorder

    phase 3 small molecule active

    1 trial

  4. Placebo, XPF-010

    Xenon Pharmaceuticals

    Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)

    phase 3 small molecule active

    1 trial

  5. XEN1101

    Xenon Pharmaceuticals

    Primary Generalized Tonic-Clonic Seizures

    phase 3 small molecule active

    1 trial

  6. XEN1101

    Xenon Pharmaceuticals

    Focal Epilepsy

    phase 3 small molecule active

    2 trials

  7. XEN1101

    Xenon Pharmaceuticals

    Focal Onset Seizures

    phase 3 small molecule active

    2 trials

  8. XEN496

    Xenon Pharmaceuticals

    Epilepsy

    phase 3 small molecule terminated

    2 trials

  9. XPF-010

    Xenon Pharmaceuticals

    Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)

    phase 3 small molecule active

    1 trial

  10. XPF-010, Placebo to match XPF-010

    Xenon Pharmaceuticals

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  11. XEN1101 10 mg

    Xenon Pharmaceuticals

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  12. XPF-001

    Xenon Pharmaceuticals

    Dental Pain

    phase 2 small molecule completed

    1 trial

  13. XPF-001

    Xenon Pharmaceuticals

    Primary Erythromelalgia

    phase 2 small molecule completed

    1 trial

  14. XPF-002

    Xenon Pharmaceuticals

    Primary Erythromelalgia

    phase 2 small molecule completed

    1 trial

  15. XPF-002

    Xenon Pharmaceuticals

    Postherpetic Neuralgia

    phase 2 small molecule completed

    1 trial

  16. XPF-005

    Xenon Pharmaceuticals

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  17. XPF-010, XPF-008, XEN1101 placebo

    Xenon Pharmaceuticals

    Adult focal (partial onset) epilepsy

    phase 2 small molecule active

    1 trial

  18. 14C-XEN1101

    Xenon Pharmaceuticals

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  19. XEN901

    Xenon Pharmaceuticals

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  20. XPF-001

    Xenon Pharmaceuticals

    Healthy Human Volunteers

    phase 1 small molecule completed

    1 trial

  21. XPF-008

    Xenon Pharmaceuticals

    Healthy Male Volunteers

    phase 1 small molecule completed

    1 trial

  22. XPF-008

    Xenon Pharmaceuticals

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources